Clozapine is associated with an increased risk of Hodgkin and non-Hodgkin lymphoma

Leukemia

Clinical and molecular characteristics of paediatric mature B-cell acute lymphocytic leukaemia and non-Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups

Br J Haematol

Zhao J, Liu TF, Wu KF, Yang LC, Xu XJ, Lu J, Shao JB, Li F, Ma FT, Guo X, Li H, Liu AG, Wang NL, Shen HP, Li Y, Liu SX, Liang CD, Shen SH, Fang YJ, Gao YJ

doi: 10.1111/bjh.20011

Lymphoma

Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group

Leukemia

Eichenauer DA, Basaran A, Bühnen I, Fuchs M, von Tresckow B, Rosenwald A, Hansmann ML, Bernd HW, Borchmann P, Klapper W, Hartmann S

doi: 10.1038/s41375-025-02641-3

Lymphoma

PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study

Leuk Lymphoma

Jin J, Meng DD, Wen Y, Zhang QL, Lv FF, Chen GL, Ma XJ, Yu BH, Zhang SJ, Liu C, Xia ZG

doi: 10.1080/10428194.2024.2447888

Lymphoma

Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents

Br J Haematol

Mato S, Carità L, Colmenero A, Andrés M, Balagué O, Andión M, Astigarraga I, Celis V, Mendoza C, Guerra-García P, Valero L, Galera A, Tallón M, Pol M, Castrejón-de-Anta N, Frauenfeld L, Garcia N, Campo E, Salaverria I, Verdú-Amorós J

doi: 10.1111/bjh.20012

Lymphoma

Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma

J Clin Oncol

Heger JM, Mammadova L, Mattlener J, Sobesky S, Cirillo M, Altmüller J, Kirst E, Reinke S, Klapper W, Bröckelmann PJ, Ferdinandus J, Kaul H, Schneider G, Schneider J, Schleifenbaum JK, Ullrich RT, Freihammer M, Awerkiew S, Lohmann M, Klein F, Nürnberg P, Hallek M, Rossi D, Mauz-Körholz C, Gattenlöhner S, Bräuninger A, Borchmann P, von Tresckow B, Borchmann S

doi: 10.1200/JCO.23.01867

Lymphoma

Analysis of Real-World Progression and Insufficient Response Variables and Related Endpoints Among Patients with Non-Hodgkin Lymphoma

Adv Ther

Richey M, Fullerton C, Zhang Q, Williams T, Donnelly D, Wise HC, Dolor A, Wadé N, Magee K

doi: 10.1007/s12325-025-03143-5

Lymphoma

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO Cohort Study analysis

Blood

Abro B, Maurer MJ, Habermann TM, Burack R, Chapman JR, Cohen JB, Friedberg JW, Inghirami GG, Kahl BS, Larson MC, Link BL, Lossos IS, Martin P, McDonnell T, Nastoupil LJ, Riska S, Syrbu SI, Vega F, Vij K, Flowers CR, Cerhan JR, Jaye DL, Feldman AL

doi: 10.1182/blood.2024025681

Lymphoma

Combination of fixed low-dose nivolumab and bendamustine in children with high-risk relapsed/refractory classical Hodgkin lymphoma

Br J Haematol

Srinivasan S, Narayan A, Dhamne C, Chichra A, Khemani P, Dhariwal N, Ranjan R, Shah S, Shet T, Gollamudi VRM, Roy Moulik N, Banavali SD, Narula G

doi: 10.1111/bjh.20148

Multiple Myeloma (MM)

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

Blood Cancer J

Rajkumar SV, Mateos MV, Schaeffer M, Lin X, Bathija S, Gupta-Werner N, Lam A, Carson R, Dennis R, Kaila S, Matt K, Duran J, Lonial S

doi: 10.1038/s41408-024-01170-z

Related content

Clinical and molecular characteristics of paediatric mature B-cell acute lymphocytic leukaemia and non-Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups

Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group

PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study

Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents

Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma

Analysis of Real-World Progression and Insufficient Response Variables and Related Endpoints Among Patients with Non-Hodgkin Lymphoma

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO Cohort Study analysis

Combination of fixed low-dose nivolumab and bendamustine in children with high-risk relapsed/refractory classical Hodgkin lymphoma

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database